Canil, G.; Orleni, M.; Posocco, B.; Gagno, S.; Bignucolo, A.; Montico, M.; Roncato, R.; Corsetti, S.; Bartoletti, M.; Toffoli, G.
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring. Pharmaceutics 2023, 15, 1524.
https://doi.org/10.3390/pharmaceutics15051524
AMA Style
Canil G, Orleni M, Posocco B, Gagno S, Bignucolo A, Montico M, Roncato R, Corsetti S, Bartoletti M, Toffoli G.
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring. Pharmaceutics. 2023; 15(5):1524.
https://doi.org/10.3390/pharmaceutics15051524
Chicago/Turabian Style
Canil, Giovanni, Marco Orleni, Bianca Posocco, Sara Gagno, Alessia Bignucolo, Marcella Montico, Rossana Roncato, Serena Corsetti, Michele Bartoletti, and Giuseppe Toffoli.
2023. "LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring" Pharmaceutics 15, no. 5: 1524.
https://doi.org/10.3390/pharmaceutics15051524
APA Style
Canil, G., Orleni, M., Posocco, B., Gagno, S., Bignucolo, A., Montico, M., Roncato, R., Corsetti, S., Bartoletti, M., & Toffoli, G.
(2023). LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring. Pharmaceutics, 15(5), 1524.
https://doi.org/10.3390/pharmaceutics15051524
